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Abstract Case description A case of severe metoclo-
pramide-induced akathisia in a breast cancer patient being
treated with chemotherapy is presented, eventually culmi-
nating in hospital admission. In retrospect, this adverse
effect was not recognized for several weeks because the
prescription had not been properly recorded in the chart,
the patient initially denied using the drug, and extensive
psychological adjustment difﬁculties were also present.
Conclusion Movement disorders as an adverse effect of
metoclopramide have been described on a regular basis
over the past decades. Case reports such as this conﬁrm
there is under-recognition of adverse effects and emphasize
the need to take a comprehensive medication history and
recognize well known side effects of medications such as
metoclopramide.
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Impact of ﬁndings on clinical practice
• There is under-recognition of movement disorders as a
side effects of metoclopramide by clinicians.
• Patients who are prescribed metoclopramide should be
educated not only about its efﬁcacy and relative safety,
but also about movement disorders as a potential side
effect.
• Metoclopramide-induced movement disorders are eas-
ily missed in medically complex cases, especially when
other explanations seem likely to the clinician.
Introduction
Nausea and vomiting are frequently occurring complaints
that can present acutely, e.g. with migraine attacks, post-
surgery or during chemotherapy for cancer, or as a part of
chronic conditions such as medically unexplained abdom-
inal symptoms (‘‘dyspepsia’’) or diabetic gastroparesis. As
a consequence, anti-emetic drugs are frequently prescribed,
both in general practice and in the hospital.
With one of these anti-emetics, metoclopramide,
extensive experience has been acquired in the course of
several decades, during which time it has become regarded
as generally effective and safe. Furthermore, reassuring
data were recently published regarding its safety in the ﬁrst
trimester of pregnancy [1].
However, metoclopramide is a peripherally and cen-
trally acting dopamine (DA) antagonist and is therefore
associated with the occurrence of sometimes severe psy-
chomotor adverse effects [2, 3]. Although reports speciﬁ-
cally on metoclopramide-induced psychomotor adverse
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the same period reports of under-recognition of these
adverse effects by clinicians appeared [4–6]. Possibly in
relationship with under-recognition, the Netherlands
Pharmacovigilance Centre recently reported having
received only 12 reports on metoclopramide-induced
dystonias and tardive dyskinesias [7].
Several factors contribute to this under-recognition,
including lack of awareness of clinicians and failure to
make speciﬁc inquiries with patients, especially if meto-
clopramide is administered on an outpatient basis. In
addition to this, situations can arise in which other expla-
nations such as evident difﬁculties coping with disease
seem likely to the clinician or when clinicians fail to
explicitly state a differential-diagnosis that incorporates the
side effects of drugs.
In this case, the patients’ distress was initially attributed
to an adjustment disorder but eventually metoclopramide-
induced akathisia was diagnosed. Making a diagnosis was
also difﬁcult, due to the lack of proper documentation of
the prescription of metoclopramide. This might have been
related to the use of this drug as a routine for chemother-
apeutic regimens.
Case description
A 58-year-old woman, divorced and living with two chil-
dren aged around 18 years, was diagnosed with locally
advanced breast cancer 2 years before the current event.
Primary treatment consisted of chemotherapy, mastectomy
and locoregional radiotherapy. During follow-up, the on-
cologists repeatedly recorded various somatic complaints
without organic substrate as well as psychological distress.
Four months before the event, the patient was diagnosed
with metastatic disease consisting of liver and bone
metastases and CMF-chemotherapy, containing cyclo-
phosphamide, methotrexate and 5-ﬂuorouracil, in combi-
nation with trastuzumab was initiated. At the time of
psychiatric referral, the ﬁrst part of the third course of
CMF-chemotherapy had been administered.
After the diagnosis of recurrent metastatic disease, and
before the start of chemotherapy, the patient was referred
to the Psycho-oncology Service, for additional psycholog-
ical support. There she was considered to be overwhelmed
by the bad news of the recurrence of the cancer for which
there was no curative treatment option anymore, to have
limited coping abilities, a tendency to react passively, and
restricted abilities to beneﬁt from psychotherapy. She had
been using oxazepam and temazepam for a considerable
time period. Also, some 15 years ago, she had been
admitted to a psychiatric facility for unspeciﬁed problems.
Four weeks before hospital admission, she presented
vague complaints of ‘‘restlessness’’ to her GP and her
oncologist which were attributed to ‘‘hyperventilation’’.
The weekend immediately preceding admission, she
frequently phoned the GP and the oncology department of
the hospital and was ﬁnally seen by the oncologist on call.
She complained of restlessness and of insomnia for several
days. Physical examination and laboratory tests were
unremarkable. After various fruitless efforts to reassure
her, she was admitted to the oncology ward. For purposes
of sedation, pipamperon 40 mg was added to the benzo-
diazepines already used and a psychiatric referral was
arranged for the following day.
During psychiatric consultation, the patient was seen
pacing up and down the corridor of the oncology ward.
When spoken separately, she was unable to remain seated
on a chair and she kept walking up and down the room: a
classic presentation of akathisia. In addition to this, the
general impression was one of severe suffering: she was
clingy and dependent, appeared both desperate and dys-
phoric, and taking a history was only possible to a limited
degree as the patient constantly iterated: ‘‘I want other
medication’’, ‘‘Don’t you have other medication for me’’
and ‘‘I can’t stand this any longer’’. She performed well on
simple tests for registration, recall and concentration, her
consciousness was not impaired, she was not grossly
incoherent, denied having delusions or hallucinations, her
mood was difﬁcult to assess but was probably best
described as despondent, and she denied suicidal ideation.
She denied having a history of anxiety disorders such as
panic attacks or phobias and denied excessive alcohol use.
After having lost her own mother to cancer 40 years ago,
she had always been afraid of developing and dying of
cancer.
In spite of the unmistakable clinical picture of akathisia,
initially, we considered an adjustment disorder as she
denied using drugs other than benzodiazepines and para-
cetamol. Only after repeated questioning and additional
checking with different outpatient pharmacies, it became
clear that at the initiation of CMF-chemotherapy she had
been prescribed a large quantity of metoclopramide sup-
positories (20 mg) to use in case of nausea or vomiting. For
reasons that she could not clarify, she had begun using
these suppositories on a regular basis 2–4 times a day over
the past weeks. Probably because prescribing metoclopra-
mide was routinely done at the start of chemotherapy, no
entry of this prescription had been made in her medical
chart.
The patient and her family were informed of the role of
metoclopramide in her agitation, she was advised to stop
the drug, and was discharged. That same evening, however,
she was readmitted with anxiety and suicidal ideation. She
received temazepam and one dose of haloperidol 1 mg
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time and did not recur, while she continued on the same
dose of benzodiazepines as before, but without metoclo-
pramide and haloperidol. Afterwards, on genotyping, no
variant alleles of cytochrome P450 2D6 with diminished or
absent metabolic activity possibly predisposing for psy-
chomotor side effects of metoclopramide were found [8].
Discussion
Neuroleptic-induced acute akathisia is deﬁned as a com-
bination of subjective complaints of restlessness (including
amongst others dysphoria and anxiety) and at least one of
the following observed movements: ﬁdgety movements or
swinging of the legs while seated, rocking from foot to foot
or ‘‘walking on the spot’’ while standing, pacing to relieve
the restlessness, or an inability to sit or stand still for at
least several minutes. Akathisia usually develops within
weeks after initiation or dose increase of a neuroleptic
drug, can be severe and may be associated with dysphoria,
irritability, aggression and suicide attempts [9].
All DA-receptor blocking drugs can cause akathisia and
as all antipsychotic drugs impact on DA-receptors, aka-
thisia is a frequently occurring side effect of antipsychotics.
As a potent DA-receptor blocking drug, metoclopramide is
associated with psychomotor side effects, most notably
acute dystonias, akathisia and parkinsonism and has prob-
ably some efﬁcacy as an antipsychotic [2, 3, 10].
In this case, in concordance with our overall experience
with similar cases, it was quite difﬁcult to convince the
clinicians that the psychomotor side effects were in fact
caused by metoclopramide, a drug that is commonly pre-
scribed without causing much trouble. This generally
benign side effect proﬁle might explain that the awareness
of clinicians of psychomotor side effects of metoclopra-
mide is sometimes lacking.
Conclusion
This patient displayed the classical syndrome of akathisia
as a probable adverse effect of metoclopramide and
highlights the psychomotor side effects of metoclopramide
once more. It also illustrates the importance of routinely
incorporating side effects of drugs in the differential
diagnosis, also when alternative explanations (such as
difﬁculties of the patient to adjust psychologically to dis-
ease) appear plausible.
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